Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 8/20 | 0.38 |
| ▸ | SOS1 | Q07889 | 2/20 | 0.37 |
| ▸ | SMYD3 | Q9H7B4 | 5/20 | 0.36 |
| ▸ | TNKS | O95271 | 1/20 | 0.35 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | DRD3 | P35462 | 1/20 | 0.35 |
| ▸ | HTR1A | P08908 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30014467 | 1.00 | FFAR4 (0.38) | FFAR4SOS1SMYD3TNKSPARP1 | |
| SCHEMBL27123175 | 0.92 | HTR1A (0.39) | TNKSPARP1HTR1A | |
| SCHEMBL30864049 | 0.90 | FFAR4 (0.40) | FFAR4SOS1KMT2ADRD3 | |
| SCHEMBL29892407 | 0.89 | DDB1 (0.40) | FFAR4SOS1SMYD3TNKSPARP1 | |
| SCHEMBL30267237 | 0.89 | LIPG (0.40) | SMYD3TNKSPARP1HTR1A | |
| SCHEMBL27118484 | 0.88 | FFAR4 (0.45) | FFAR4SOS1KMT2ADRD3 | |
| SCHEMBL29893498 | 0.88 | FFAR4 (0.45) | FFAR4SOS1KMT2ADRD3 | |
| SCHEMBL30864092 | 0.87 | FFAR4 (0.39) | FFAR4SOS1DRD3 | |
| SCHEMBL30864018 | 0.85 | FFAR4 (0.41) | FFAR4SOS1DRD3 | |
| SCHEMBL25920200 | 0.85 | MGLL (0.38) | FFAR4TNKSPARP1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240261418-A1 | SOS1 DEGRADING AGENT AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | LEADINGTAC PHARMACEUTICAL (SHAOXING) CO., LTD. (CN) | 2024-08-08 | — | — | US | disclosed |
| EP-4328219-A1 | SOS1 DEGRADING AGENT AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Shanghai Leadingtac Pharmaceutical Co. Ltd. (CN) | 2024-02-28 | — | — | EP | disclosed |
| EP-4328219-A1 | SOS1 DEGRADING AGENT AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Shanghai Leadingtac Pharmaceutical Co. Ltd. (CN) | 2024-02-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240261418-A1 | SOS1 DEGRADING AGENT AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | SOS1, RAC1, RSU1 | FFAR4 3977/4885SOS1 1/4885SMYD3 4063/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.